Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Barish H. Edil

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1467-9723; OpenAlex author ID A5083184392. Sources: OpenAlex.

Their work

Papers
41 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
137
Papers, trials and grants by year

2011: 6 papers · 2012: 7 papers · 2013: 6 papers · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: 2 papers · 2026: 1 paper

Papers 41

  1. Peptide-Based Probe Targeting Angiotensin Type‑1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography. Co-author DOI 10.1021/cbmi.5c00128↗
  2. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  3. RETRACTED: Thomas et al. Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Cancers 20… Co-author DOI 10.3390/cancers17243888↗
  4. Theranostic nanoparticles for detection and treatment of pancreatic cancer. Co-author DOI 10.1002/wnan.1983↗
  5. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampulla… Co-author DOI 10.1016/j.amjsurg.2024.115820↗
  6. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  7. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  8. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. Co-author DOI 10.1093/oncolo/oyae178↗
  9. Innovative Imaging Techniques Used to Evaluate Borderline-Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jss.2022.10.008↗
  10. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722↗
  11. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  12. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancrea… Co-author DOI 10.1053/j.gastro.2019.10.038↗
  13. RETRACTED: Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Co-author DOI 10.3390/cancers12082279↗
  14. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pan… Co-author DOI 10.1002/jso.25004↗
  15. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Last author DOI 10.1007/s00464-017-5915-0↗
  16. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. Last author PMID 29950957↗
  17. Portal Venous Stenting in Locally Advanced Pancreatic Cancer to Decrease Risk of Thrombosis Before Irreversible Electroporation: A Case Report and Review of th… Last author DOI 10.1089/crpc.2016.0022↗
  18. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  19. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2015.0668↗
  20. Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer. Co-author DOI 10.1245/s10434-014-4293-2↗
  21. Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Co-author DOI 10.3978/j.issn.1000-9604.2015.05.01↗
  22. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. First author DOI 10.1097/md.0000000000000198↗
  23. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. First author DOI 10.1007/s11605-012-2066-4↗
  24. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relat… Co-author DOI 10.1007/s13566-013-0115-6↗
  25. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  26. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic… Co-author DOI 10.1016/j.ijrobp.2013.06.2039↗
  27. Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor v… Co-author DOI 10.1245/s10434-013-3262-5↗
  28. Vaccine therapy for pancreatic cancer. Co-author DOI 10.4161/onci.26662↗
  29. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Co-author DOI 10.1002/cncr.26553↗
  30. Factors influencing survival in patients undergoing palliative bypass for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.23047↗
  31. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. Co-author DOI 10.1007/s11605-011-1811-4↗
  32. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. Co-author DOI 10.1007/s11605-012-1923-5↗
  33. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. Co-author DOI 10.1016/j.jamcollsurg.2011.09.022↗
  34. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: impli… Co-author DOI 10.1016/j.radonc.2012.07.004↗
  35. Vaccines for pancreatic cancer. Co-author DOI 10.1097/ppo.0b013e3182756903↗
  36. Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.21883↗
  37. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. Co-author DOI 10.1007/s11605-011-1605-8↗
  38. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. Co-author DOI 10.1007/s11605-011-1665-9↗
  39. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Co-author DOI 10.1007/s13193-011-0073-7↗
  40. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Co-author DOI 10.1245/s10434-011-1745-9↗
  41. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0019390↗

Closest collaborators

The 25 strongest of 137 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard David Schulick · 24 shared papers, 2011–2024 · strength 1.12
  2. Lacey R. McNally · 5 shared papers, 2020–2026 · strength 0.97
  3. Ajay Jain · 4 shared papers, 2023–2024 · strength 0.64
  4. Susanna Varkey Ulahannan · 3 shared papers, 2024–2026 · strength 0.58
  5. Joseph M. Herman · 18 shared papers, 2011–2021 · strength 0.56
  6. Martin D. McCarter · 6 shared papers, 2014–2024 · strength 0.55
  7. William M. MacCuaig · 3 shared papers, 2020–2025 · strength 0.49
  8. Lei Zheng · 10 shared papers, 2011–2022 · strength 0.49
  9. Rohit Singh · 2 shared papers, 2024–2026 · strength 0.49
  10. Happy Agarwal · 2 shared papers, 2024–2026 · strength 0.49
  11. Ana Gleisner · 4 shared papers, 2018–2024 · strength 0.45
  12. Christopher Lee Wolfgang · 16 shared papers, 2011–2016 · strength 0.44
  13. Alessandro Paniccia · 6 shared papers, 2014–2018 · strength 0.38
  14. Isabel S. Dennahy · 2 shared papers, 2023–2024 · strength 0.36
  15. Timothy Michael Pawlik · 13 shared papers, 2011–2013 · strength 0.35
  16. Daniel A. Laheru · 10 shared papers, 2011–2021 · strength 0.35
  17. Csaba Gajdos · 5 shared papers, 2014–2018 · strength 0.34
  18. Ralph H. Hruban MD · 11 shared papers, 2011–2016 · strength 0.31
  19. Alexandra Thomas · 2 shared papers, 2020–2025 · strength 0.31
  20. Wenyuan Yin · 2 shared papers, 2020–2025 · strength 0.31
  21. Michael E. Egger · 2 shared papers, 2020–2025 · strength 0.31
  22. Kamiya Mehla · 2 shared papers, 2024 · strength 0.28
  23. Rosa F. Hwang · 2 shared papers, 2024 · strength 0.28
  24. Vikrant Rai · 2 shared papers, 2024 · strength 0.28
  25. Divya Murthy · 2 shared papers, 2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.